vs

Side-by-side financial comparison of Open Lending Corp (LPRO) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Open Lending Corp is the larger business by last-quarter revenue ($19.3M vs $12.5M, roughly 1.6× Avidity Biosciences, Inc.). On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 134.0%). Open Lending Corp produced more free cash flow last quarter ($-3.3M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -20.7%).

Open Library is an online project intended to create "one web page for every book ever published". Created by Aaron Swartz, Brewster Kahle, Alexis Rossi, Anand Chitipothu, and Rebecca Hargrave Malamud, Open Library is a project of the Internet Archive, a nonprofit organization. It has been funded in part by grants from the California State Library and the Kahle/Austin Foundation. Open Library provides online digital copies in multiple formats, created from images of many public domain, out-of...

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

LPRO vs RNA — Head-to-Head

Bigger by revenue
LPRO
LPRO
1.6× larger
LPRO
$19.3M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+300.0% gap
RNA
434.0%
134.0%
LPRO
More free cash flow
LPRO
LPRO
$153.6M more FCF
LPRO
$-3.3M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-20.7%
LPRO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LPRO
LPRO
RNA
RNA
Revenue
$19.3M
$12.5M
Net Profit
$-174.4M
Gross Margin
76.0%
Operating Margin
3.9%
-1513.5%
Net Margin
-1398.3%
Revenue YoY
134.0%
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$-0.00
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LPRO
LPRO
RNA
RNA
Q4 25
$19.3M
Q3 25
$24.2M
$12.5M
Q2 25
$25.3M
$3.8M
Q1 25
$24.4M
$1.6M
Q4 24
$-56.9M
$3.0M
Q3 24
$23.5M
$2.3M
Q2 24
$26.7M
$2.0M
Q1 24
$30.7M
$3.5M
Net Profit
LPRO
LPRO
RNA
RNA
Q4 25
Q3 25
$-7.6M
$-174.4M
Q2 25
$1.0M
$-157.3M
Q1 25
$617.0K
$-115.8M
Q4 24
$-102.3M
Q3 24
$1.4M
$-80.4M
Q2 24
$2.9M
$-70.8M
Q1 24
$5.1M
$-68.9M
Gross Margin
LPRO
LPRO
RNA
RNA
Q4 25
76.0%
Q3 25
78.0%
Q2 25
78.2%
Q1 25
75.1%
Q4 24
111.0%
Q3 24
73.9%
Q2 24
78.6%
Q1 24
81.3%
Operating Margin
LPRO
LPRO
RNA
RNA
Q4 25
3.9%
Q3 25
-31.9%
-1513.5%
Q2 25
4.6%
-4448.7%
Q1 25
3.1%
-8360.9%
Q4 24
138.0%
-4069.6%
Q3 24
7.9%
-4200.9%
Q2 24
14.9%
-4040.4%
Q1 24
23.8%
-2178.6%
Net Margin
LPRO
LPRO
RNA
RNA
Q4 25
Q3 25
-31.3%
-1398.3%
Q2 25
4.1%
-4089.3%
Q1 25
2.5%
-7360.0%
Q4 24
-3439.5%
Q3 24
6.1%
-3441.7%
Q2 24
10.9%
-3461.8%
Q1 24
16.5%
-1943.4%
EPS (diluted)
LPRO
LPRO
RNA
RNA
Q4 25
$-0.00
Q3 25
$-0.06
$-1.27
Q2 25
$0.01
$-1.21
Q1 25
$0.01
$-0.90
Q4 24
$-1.20
$-0.80
Q3 24
$0.01
$-0.65
Q2 24
$0.02
$-0.65
Q1 24
$0.04
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LPRO
LPRO
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$176.6M
$350.2M
Total DebtLower is stronger
$84.8M
Stockholders' EquityBook value
$75.0M
$1.9B
Total Assets
$236.7M
$2.1B
Debt / EquityLower = less leverage
1.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LPRO
LPRO
RNA
RNA
Q4 25
$176.6M
Q3 25
$222.1M
$350.2M
Q2 25
$230.7M
$243.9M
Q1 25
$236.2M
$254.2M
Q4 24
$243.2M
$219.9M
Q3 24
$250.2M
$370.2M
Q2 24
$248.0M
$575.8M
Q1 24
$247.0M
$471.4M
Total Debt
LPRO
LPRO
RNA
RNA
Q4 25
$84.8M
Q3 25
$134.4M
Q2 25
$136.1M
Q1 25
$137.9M
Q4 24
$139.7M
Q3 24
$141.5M
Q2 24
$143.3M
Q1 24
$143.2M
Stockholders' Equity
LPRO
LPRO
RNA
RNA
Q4 25
$75.0M
Q3 25
$72.8M
$1.9B
Q2 25
$78.9M
$1.2B
Q1 25
$79.8M
$1.3B
Q4 24
$78.1M
$1.4B
Q3 24
$220.5M
$1.5B
Q2 24
$216.8M
$1.2B
Q1 24
$211.5M
$830.9M
Total Assets
LPRO
LPRO
RNA
RNA
Q4 25
$236.7M
Q3 25
$287.7M
$2.1B
Q2 25
$296.7M
$1.4B
Q1 25
$304.2M
$1.5B
Q4 24
$296.4M
$1.6B
Q3 24
$395.7M
$1.6B
Q2 24
$382.8M
$1.3B
Q1 24
$380.6M
$951.5M
Debt / Equity
LPRO
LPRO
RNA
RNA
Q4 25
1.13×
Q3 25
1.84×
Q2 25
1.72×
Q1 25
1.73×
Q4 24
1.79×
Q3 24
0.64×
Q2 24
0.66×
Q1 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LPRO
LPRO
RNA
RNA
Operating Cash FlowLast quarter
$-3.2M
$-156.2M
Free Cash FlowOCF − Capex
$-3.3M
$-156.9M
FCF MarginFCF / Revenue
-16.8%
-1257.6%
Capex IntensityCapex / Revenue
0.3%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LPRO
LPRO
RNA
RNA
Q4 25
$-3.2M
Q3 25
$-5.7M
$-156.2M
Q2 25
$848.0K
$-199.7M
Q1 25
$-3.8M
$-124.8M
Q4 24
$17.6M
$-99.9M
Q3 24
$11.4M
$-65.6M
Q2 24
$-1.4M
$-65.0M
Q1 24
$11.0M
$-70.4M
Free Cash Flow
LPRO
LPRO
RNA
RNA
Q4 25
$-3.3M
Q3 25
$-156.9M
Q2 25
$837.0K
$-203.0M
Q1 25
$-3.9M
$-128.6M
Q4 24
$17.4M
$-103.8M
Q3 24
$11.3M
$-67.3M
Q2 24
$-1.5M
$-65.5M
Q1 24
$-71.3M
FCF Margin
LPRO
LPRO
RNA
RNA
Q4 25
-16.8%
Q3 25
-1257.6%
Q2 25
3.3%
-5277.1%
Q1 25
-15.9%
-8174.3%
Q4 24
-30.6%
-3491.0%
Q3 24
48.0%
-2881.8%
Q2 24
-5.5%
-3204.6%
Q1 24
-2012.3%
Capex Intensity
LPRO
LPRO
RNA
RNA
Q4 25
0.3%
Q3 25
0.0%
5.7%
Q2 25
0.0%
86.9%
Q1 25
0.2%
238.6%
Q4 24
-0.3%
131.7%
Q3 24
0.5%
72.9%
Q2 24
0.2%
26.0%
Q1 24
0.0%
25.8%
Cash Conversion
LPRO
LPRO
RNA
RNA
Q4 25
Q3 25
Q2 25
0.82×
Q1 25
-6.22×
Q4 24
Q3 24
7.92×
Q2 24
-0.48×
Q1 24
2.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons